Latest Breaking News On - Glaxosmithkline pharmaceuticalslimited - Page 1 : comparemela.com

GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasonefuroate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for ChronicObstructive Pulmonary Disease (COPD) patients in a once-daily regime.

Indian copdpatientsTrelegy elliptaDeepak talwarGlaxosmithkline pharmaceuticalslimitedRashmi hegdeGlaxosmithkline pharmaceuticalsGlaxosmithkline pharmaceuticals limitedChronicobstructive pulmonary diseaseDrugs controller generalExecutive vice presidentCritical care medicine